Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;18(6):4993-5000.
doi: 10.3892/etm.2019.7858. Epub 2019 Aug 6.

Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania

Horia T Stanca  1 , Simona Stanca  2 , Bogdana Tabacaru  1 , Madalina Boruga  3 , Florian Balta  1
Affiliations

Bevacizumab in Wet AMD treatment: A tribute to the thirteen years of experience from the beginning of the anti-VEGF era in Romania

Horia T Stanca et al. Exp Ther Med. 2019 Dec.

Abstract

This study aimed to identify and describe anatomical and functional changes on short (1-3 months) and medium (6-12 months) term after intravitreal injections of bevacizumab (Avastin, Genentech) in patients with choroidal neovascularization (CNV) in the context of exudative form of age-related macular degeneration (AMD). We performed a retrospective, analytical, interventional study, based on a series of cases with exudative form of AMD, which also comprised a prospective component related to the inclusion and treatment of the patients with a very new interventional method for that time (2006) and the follow-up of the effects of intravitreal injection of bevacizumab (1.25 mg) therapy in three monthly doses for short (1-3 months) and medium (6-18 months) periods of time. The follow-up of these patients was made by determining visual acuity (VA) as best corrected visual acuity (BCVA) at baseline and at every visit, slit lamp examination with contact or noncontact lenses each time, and optical coherence tomography and/or angiofluorography, applied only for certain patients, at various times of the study. In total, 376 intravitreal injections were administered to 117 eyes of 96 patients. The VA improved in the assessment of 3 months in 77 eyes (66%), either subjective (by the patient) or objectively quantified (by the physician). In 40 eyes (34%), there was no change in VA. In patients for whom optical coherence tomography could be performed, a significant reduction of the macula's thickness was found. The use of bevacizumab in subretinal neovascular membrane treatment is effective and safe on short and medium term, with the improvement of BCVA and reduction of macular edema in a significant number of cases.

Keywords: bevacizumab; central foveal thickness; choroidal neovascularization; visual acuity; wet AMD.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The evolution trend of the average VA.
Figure 2.
Figure 2.
The evolution trend of the average VA in time.
Figure 3.
Figure 3.
Increasing VA trend within the 9-month time interval.
Figure 4.
Figure 4.
Decreasing FT trend within the 9-month time interval.
See this image and copyright information in PMC

References

    1. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1997;104:7–21. doi: 10.1016/S0161-6420(97)30368-6. - DOI - PubMed
    1. National Eye Institute, corp-author. Statistics and Data. Prevalence of Blindness Data. https://nei.nih.gov/eyedata/pbd_tables Data Tables [online] 2007
    1. Fine SL, Berger JW, Maguire MG, Ho AC. Age-related macular degeneration. N Engl J Med. 2000;342:483–492. doi: 10.1056/NEJM200002173420707. - DOI - PubMed
    1. Ciulla TA, Harris A, Martin BJ. Ocular perfusion and age-related macular degeneration. Acta Ophthalmol Scand. 2001;79:108–115. doi: 10.1034/j.1600-0420.2001.079002108.x. - DOI - PubMed
    1. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Michels S, Marcus EN, Lenchus JD, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology. 2006;113:2002.e1–2002.e12. doi: 10.1016/j.ophtha.2006.05.070. - DOI - PubMed